Skip to main content
JOINN LABORATORIES (CHINA) CO., LTD. logo

JOINN LABORATORIES (CHINA) CO., LTD. — Investor Relations & Filings

Ticker · 603127 ISIN · CNE100002W27 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,411 across all filing types
Latest filing 2026-05-22 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 603127

About JOINN LABORATORIES (CHINA) CO., LTD.

https://www.joinnlabs.com/en/

JOINN Laboratories (China) Co., Ltd. is a premier contract research organization (CRO) specializing in non-clinical safety assessment and pharmacology services for the global pharmaceutical and biotechnology sectors. The company provides a comprehensive suite of services including toxicology, safety pharmacology, pharmacokinetics, and pharmacodynamics. It operates state-of-the-art facilities that adhere to international Good Laboratory Practice (GLP) standards, holding certifications from regulatory bodies such as the NMPA, FDA, and OECD. Beyond safety evaluation, the company offers integrated solutions for drug discovery and clinical trial support, facilitating the development of innovative therapeutics from early-stage research through regulatory submission. Its technical expertise and multi-site capabilities support a diverse range of drug modalities, including small molecules, biologics, and advanced therapies.

Recent filings

Filing Released Lang Actions
昭衍新药关于与专业投资机构合作参与投资设立基金的进展公告
Regulatory Filings Classification · 75% confidence The document is a formal disclosure by Beijing Zhaoyan New Drug Research Center Co., Ltd. on the Shanghai Stock Exchange regarding the progress of its external investment in a private equity fund. It is not an annual or interim report, earnings release, management discussion, board change, share issuance, dividend notice, or other specialized form. It details transaction terms but does not constitute a financing (debt or equity issuance) nor an acquisition under M&A forms; therefore it best fits the catch-all category for routine regulatory announcements. Under the company’s taxonomy, this is classified as a general regulatory filing.
2026-05-22 Chinese
昭衍新药董事会薪酬与考核委员会关于公司2026年A股限制性股票激励计划激励对象名单的核查意见及公示情况说明
Share Issue/Capital Change Classification · 80% confidence The document is an official listing announcement by the board’s remuneration and evaluation committee regarding the 2026 A-share restricted stock incentive plan and the verified list of incentive recipients. It does not contain full financial statements or earnings data. It announces an equity incentive plan, which constitutes a share issue or other capital change. Under the classification taxonomy, equity incentive announcements fit into Share Issue/Capital Change (SHA).
2026-05-12 Chinese
昭衍新药关于召开2025年年度股东会、2026年第一次A股类别股东会议及2026年第一次H股类别股东会议的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a formal notice to shareholders of the upcoming 2025 Annual General Meeting and first 2026 class meetings, including detailed agenda items, voting procedures, proxy forms and instructions on how to vote. This is characteristic of materials sent to shareholders to inform and solicit their votes (proxy statement), rather than the AGM presentation itself or a simple report announcement.
2026-05-12 Chinese
昭衍新药2025年年度股东会、2026年第一次A股类别股东会议及2026年第一次H股类别股东会议会议资料
Proxy Solicitation & Information Statement Classification · 92% confidence The document is the detailed meeting materials (“会议资料”) for the 2025 annual general meeting and 2026 class shareholder meetings (A-share and H-share), including agenda items, proposals for vote, voting instructions, and supporting summaries. It is provided to shareholders ahead of the meeting to solicit their votes. This matches the Proxy Solicitation & Information Statement category rather than an actual financial report or announcement of publication.
2026-05-12 Chinese
H股公告：4月月报表
Regulatory Filings Classification · 95% confidence The document is a monthly securities movement report (FF301) submitted to the Hong Kong Stock Exchange (HKEX) by Beijing Zhaoyan New Drug Research Center Co., Ltd. It details changes in registered capital, issued shares, public float confirmation, and related securities information for the month ending April 30, 2026. The document is 4304 characters long, which is relatively short and primarily consists of tabular data and confirmations about share capital and public float compliance. It does not contain financial statements, management discussion, or detailed financial results. It is a regulatory compliance report related to share capital and securities movements under HKEX Listing Rules, not an annual or interim financial report, earnings release, or management report. It is not a notice of dividend, director dealing, or M&A activity. Given the nature and length, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory compliance documents that do not fit other specific categories.
2026-05-06 Chinese
H股公告：董事会召开日期
Report Publication Announcement Classification · 90% confidence The document is a short HKEX announcement notifying shareholders of a scheduled Board meeting on April 29, 2026 to approve and release the Group’s Q1 results. It does not contain any financial figures or results itself, nor is it a management change or full quarterly report. It simply announces the timing and purpose of an upcoming report publication. Therefore, it is best classified as a Report Publication Announcement (RPA).
2026-04-17 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.